Q3 2022 Results

Company overview Financial performance Cardiovascular Financial review 2022 priorities Appendix Innovation: Pipeline overview Innovation: Clinical trials Immunology Neuroscience Oncology ianalumab - BAFF-R inhibitor NCT03217422 AMBER (CVAY736B2201) Indication Autoimmune hepatitis Phase 2 Phase Patients 80 Primary Alanine aminotransferase (ALT) normalization Outcome Measures Arms VAY736 Intervention Placebo control with conversion to active VAY736 Autoimmune hepatitis patients with incomplete response or intolerant to standard treatment of care Target Patients Read-out 2026 Milestone(s) Publication TBD 53 Investor Relations | Q3 2022 Results ianalumab - BAFF-R inhibitor NCT05126277 SIRIUS-LN (CVAY736K12301) Indication Lupus Nephritis Phase 3 Phase Patients 420 Primary Outcome Measures Arms Intervention References Abbreviations Other Frequency and percentage of participants achieving complete renal response (CRR) [ Time Frame: week 72] Arm 1: Experimental - ianalumab s.c. q4w in addition to standard of care (SoC) Arm 2: Experiemntal - ianalumab s.c. q12w in addition to SoC Arm 3: Placebo comparator - Placebo s.c. q4w in addition to SoC Parients with active Lupus Nephritis Target Patients Read-out Milestone(s) Primary 2027 Publication TBD NOVARTIS | Reimagining Medicine

View entire presentation